02132nas a2200265   4500008004100000022001400041245014200055210006900197260009700266300001200363490000600375520116200381653000901543653001301552653001301565653002501578653001401603653001801617100001901635700001801654700002101672700002601693700001901719856012801738       2015                        eng d  a2210-803300aLannea coromandelica attenuates glucagon and oxyntomodulin mediated cAMP formation in HEK cells stably-expressing human glucagon receptor0 aLannea coromandelica attenuates glucagon and oxyntomodulin media  aOFFICE JENA, P O BOX 100537, 07705 JENA, GERMANYbELSEVIER GMBH, URBAN & FISCHER VERLAGcSEP  a153-1570 v53 a<p>Antagonism of glucagon is a potential therapeutic approach for Type 2 diabetes mellitus (T2DM). The bark extract of Lannea coromandelica has been reported to have hypoglycemic or anti-diabetic effects on animal models and human subjects. The aim of this study was to elucidate the molecular mechanisms of L. coromandelica extract as a glucagon receptor antagonist. The aqueous extract of L. coromandelica bark attenuated glucagon-mediated cAMP formation in a concentration dependent manner with an IC50 value of 4.24 +/- 1.31 mu g/ml. It shifted a concentration response curve of glucagon towards the right with a 4, 21 and 40-fold change in IC50 at 6.25, 12.5 and 25 mu g/ml of extract, respectively. Additionally, it attenuated an oxyntomodulin-mediated cAMP response. The extract was found specifically to inhibit glucagon mediated cAMP formation since it was ineffective in reducing cAMP levels nonspecifically-elevated by forskolin. The data support that the aqueous extract of L. coromandelica antagonizes the glucagon receptor and has the potential to reduce glucagon mediated liver glucose output. (C) 2015 Elsevier GmbH. All rights reserved.</p>10acAMP10aDiabetes10aGlucagon10aLannea coromandelica10aMechanism10aOxyntomodulin1 aWalunj, Sameer1 aGupta, Rajesh1 aJoshi, Swati, P.1 aSabharwal, Sushma, G.1 aJoshi, Kalpana  uhttps://library.ncl.res.in/content/lannea-coromandelica-attenuates-glucagon-and-oxyntomodulin-mediated-camp-formation-hek-0